EPCAM and ovarian cancer: The exploration of EpCAM-targeted therapies, such as the bispecific T-cell engaging antibodies (BiTE) that show efficacy against ovarian cancer cells, underscores the potential of EpCAM as a target for innovative therapeutic interventions.